香港股市 將在 2 小時 9 分鐘 開市

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
加入追蹤清單
5.43-0.13 (-2.34%)
收市:04:00PM EDT
5.37 -0.06 (-1.07%)
收市後: 06:50PM EDT

Aurinia Pharmaceuticals Inc.

118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com

版塊Healthcare
行業Biotechnology
全職員工300

高階主管

名稱頭銜支付行使價出生年份
Mr. Peter S. Greenleaf M.B.A.President, CEO & Director1.57M1970
Mr. Joseph M. Miller CPAChief Financial Officer883.19k1974
Mr. Matthew Maxwell Donley M.B.A.Executive Vice President of Operations & Strategy901.84k1969
Mr. Stephen P. RobertsonExecutive VP, General Counsel, Corporate Secretary & Chief Compliance Officer836.38k1982
Ms. Andrea Levin ChristopherHead of the Corporate Communications & Investor Relations
Mr. Michael R. MartinChief Business Officer350.57k1972
Ms. Sue EvansSenior Vice President of Global Regulatory Affairs
Mr. Scott HabigChief Commercial Officer1960
Dr. Gregory F. Keenan M.D.Chief Medical Officer
Dr. Ann M. Daus Ph.D.Senior Vice President of Quality
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

公司管治

截至 2024年7月1日 止,Aurinia Pharmaceuticals Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中:4;董事會:7;股東權利:2;現金賠償:6。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。